Medtronic PLC Company Insiders

MDT Stock  USD 91.87  0.34  0.37%   
Slightly above 91 percent of Medtronic PLC's insiders are activelly selling. The analysis of insiders' sentiment of trading Medtronic PLC stock suggests that a very large number of insiders are panicking at this time. Medtronic PLC employs about 95 K people. The company is managed by 47 executives with a total tenure of roughly 242 years, averaging almost 5.0 years of service per executive, having 2021.28 employees per reported executive.
Omar Ishrak  Chairman
Chairman of the Board, Chief Executive Officer
Bradley Lerman  President
Senior Vice President General Counsel, Corporate secretary

Insider Sentiment 9

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-01-24Brett A WallDisposed 12437 @ 90View
2025-01-08Brett A WallDisposed 9850 @ 80.41View
2025-01-06Emily RandallDisposed @ 79.77
2024-09-04John JamesDisposed @ 91.03
2024-08-26Tommy TubervilleDisposed @ 89.34
2024-07-09Earl BlumenauerDisposed @ 76.89
2024-07-02Kathy E. ManningDisposed @ 77.37
2024-06-18John JamesAcquired @ 79.75
2024-06-07Geoffrey MarthaDisposed 19113 @ 83.77View
2024-06-03John JamesDisposed @ 82.12
2024-04-08Michael MarinaroDisposed 854 @ 83.14View
Monitoring Medtronic PLC's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Medtronic PLC's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Medtronic PLC. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Medtronic PLC's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.

Medtronic PLC's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Medtronic PLC's future performance. Based on our forecasts, it is anticipated that Medtronic will maintain a workforce of slightly above 95000 employees by April 2025.
 
Yuan Drop
 
Covid

Medtronic PLC's latest congressional trading

Congressional trading in companies like Medtronic PLC, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Medtronic PLC by those in governmental positions are based on the same information available to the general public.
2025-02-12Representative Emily RandallAcquired Under $15KVerify
2024-12-06Representative Ro KhannaAcquired Under $15KVerify
2024-09-12Senator Tommy TubervilleAcquired $15K to $50KVerify
2024-09-06Representative John JamesAcquired Under $15KVerify
2024-09-02Representative John JamesAcquired Under $15KVerify
2024-08-16Representative Kathy ManningAcquired Under $15KVerify
2024-03-15Senator Shelley Moore CapitoAcquired Under $15KVerify
2024-03-14Senator Shelley Moore CapitoAcquired Under $15KVerify
2023-12-14Representative Debbie DingellAcquired $15K to $50KVerify
2023-06-26Representative Pete SessionsAcquired $15K to $50KVerify
2023-04-19Senator Tina SmithAcquired $100K to $250KVerify
2023-04-18Senator Tina SmithAcquired $100K to $250KVerify
2022-12-22Representative Bob GibbsAcquired $15K to $50KVerify
2022-08-07Representative Alan S LowenthalAcquired Under $15KVerify
2022-08-04Representative Alan S LowenthalAcquired Under $15KVerify
2022-06-12Senator Roy BluntAcquired $15K to $50KVerify
2022-05-05Representative William R KeatingAcquired Under $15KVerify
2021-05-25Representative Lois FrankelAcquired Under $15KVerify
2020-11-04Representative Alan S LowenthalAcquired Under $15KVerify
2020-04-10Representative Peter WelchAcquired Under $15KVerify
2019-02-28Representative Katherine M ClarkAcquired Under $15KVerify
2016-10-04Senator Thomas R CarperAcquired Under $15KVerify
2016-10-03Senator Thomas R CarperAcquired Under $15KVerify
2015-02-25Senator Gary PetersAcquired $15K to $50KVerify
2015-02-24Senator Gary PetersAcquired $15K to $50KVerify

Medtronic PLC Management Team Effectiveness

The company has Return on Asset of 0.0466 % which means that on every $100 spent on assets, it made $0.0466 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0844 %, implying that it generated $0.0844 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2025, whereas Return On Capital Employed is likely to drop 0.05 in 2025. Total Current Liabilities is likely to gain to about 13 B in 2025. Liabilities And Stockholders Equity is likely to gain to about 108.7 B in 2025

Medtronic PLC Quarterly Income Before Tax

1.54 Billion

Common Stock Shares Outstanding is likely to drop to about 1.2 B in 2025. Net Income Applicable To Common Shares is likely to drop to about 3.2 B in 2025

Medtronic PLC Workforce Comparison

Medtronic PLC is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 385,495. Medtronic PLC totals roughly 95,000 in number of employees claiming about 25% of equities under Health Care industry.

Medtronic PLC Profit Margins

The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.22 %, which entails that for every 100 dollars of revenue, it generated $0.22 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.6519
Fairly Up
Very volatile
Net Profit Margin0.180.1197
Way Up
Very volatile
Operating Profit Margin0.250.1489
Way Up
Very volatile
Pretax Profit Margin0.240.1293
Way Up
Very volatile
Return On Assets0.03680.0387
Notably Down
Slightly volatile
Return On Equity0.06660.0701
Notably Down
Slightly volatile

Medtronic PLC Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Medtronic PLC insiders, such as employees or executives, is commonly permitted as long as it does not rely on Medtronic PLC's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Medtronic PLC insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.0
12
12
 170,712 
 114,003 
2024-09-01
1.0278
37
36
 1,337,156 
 177,078 
2024-06-01
0.75
12
16
 40,419 
 49,227 
2024-03-01
0.375
3
8
 30,695 
 63,112 
2023-12-01
0.1667
1
6
 1,695 
 8,904 
2023-09-01
1.4643
41
28
 1,239,904 
 164,405 
2023-06-01
0.7143
10
14
 18,994 
 16,519 
2022-12-01
0.375
3
8
 19,035 
 42,453 
2022-09-01
2.6364
29
11
 992,938 
 141,741 
2022-06-01
0.75
9
12
 15,273 
 41,856 
2022-03-01
1.5
6
4
 263,528 
 18,441 
2021-12-01
0.5833
7
12
 114,310 
 109,034 
2021-09-01
2.0833
50
24
 954,577 
 353,536 
2021-06-01
0.7241
21
29
 85,734 
 127,976 
2021-03-01
1.3333
4
3
 30,408 
 14,968 
2020-12-01
0.8333
20
24
 299,479 
 187,592 
2020-09-01
2.2
44
20
 1,544,886 
 123,375 
2020-06-01
0.8125
13
16
 41,996 
 31,360 
2019-12-01
0.463
25
54
 463,606 
 712,142 
2019-09-01
0.9111
41
45
 1,237,216 
 334,070 
2019-06-01
0.88
22
25
 79,895 
 139,562 
2019-03-01
1.0
3
3
 17,671 
 8,227 
2018-12-01
2.0
2
1
 20,139 
 1,698 
2018-09-01
1.1944
43
36
 1,398,013 
 675,883 
2018-06-01
0.6296
17
27
 385,289 
 2,853,878 
2018-03-01
0.5
7
14
 157,732 
 330,011 
2017-09-01
1.5
33
22
 911,933 
 348,255 
2017-06-01
1.0909
12
11
 28,590 
 13,522 
2017-03-01
0.6667
12
18
 211,678 
 425,457 
2016-12-01
0.6667
2
3
 15,660 
 26,773 
2016-09-01
1.3158
50
38
 1,089,286 
 406,548 
2016-06-01
0.8462
22
26
 156,455 
 145,741 
2016-03-01
0.1538
2
13
 324,506 
 677,717 
2015-12-01
0.25
1
4
 15,401 
 40,665 
2015-09-01
2.0
32
16
 839,875 
 145,854 
2015-06-01
3.8571
27
7
 61,114 
 135,272 
2015-03-01
1.8081
179
99
 6,014,655 
 1,992,706 
2014-12-01
0.3
3
10
 2,581 
 89,399 
2014-09-01
2.0667
31
15
 535,650 
 106,643 
2014-06-01
1.8333
11
6
 25,489 
 11,004 
2013-12-01
1.3333
4
3
 99,702 
 40,928 
2013-09-01
0.96
24
25
 360,989 
 398,990 
2013-06-01
1.1875
19
16
 204,068 
 378,387 
2012-12-01
3.5
7
2
 15,566 
 38,196 
2012-09-01
2.4
12
5
 429,430 
 17,440 
2012-03-01
0.75
3
4
 59,962 
 118,702 
2011-12-01
0.0667
1
15
 1,248 
 38,798 
2011-09-01
1.2143
17
14
 598,918 
 62,618 
2011-06-01
9.0
9
1
 49,273 
 380.00 
2010-12-01
0.25
2
8
 101,348 
 39,806 
2010-09-01
5.0
20
4
 895,815 
 12,364 
2010-06-01
4.0
20
5
 91,400 
 8,127 
2010-03-01
0.6
3
5
 43,708 
 11,844 
2009-12-01
0.6429
9
14
 127,612 
 66,635 
2009-09-01
5.3333
16
3
 673,724 
 1,085 
2009-06-01
5.3333
16
3
 40,521 
 7,652 
2008-12-01
1.9091
21
11
 766,832 
 38,424 
2008-09-01
1.3333
8
6
 160,896 
 16,205 
2008-06-01
1.6111
29
18
 143,217 
 141,362 
2008-03-01
66.0
66
1
 255,093 
 1,504 
2007-12-01
1.9167
23
12
 607,954 
 61,661 
2007-09-01
1.6
24
15
 610,305 
 1,020,372 
2007-06-01
1.0541
39
37
 149,614 
 66,887 
2007-03-01
0.4091
9
22
 42,773 
 76,943 
2006-12-01
1.6667
25
15
 666,270 
 198,298 
2006-09-01
5.8333
35
6
 144,798 
 89,128 
2006-06-01
1.2308
16
13
 183,923 
 18,197 
2006-03-01
1.6667
5
3
 23,099 
 33,592 
2005-12-01
1.0
13
13
 594,379 
 16,345 
2005-09-01
2.25
27
12
 103,113 
 187,418 
2005-06-01
1.0
37
37
 387,841 
 526,488 
2005-03-01
0.4
2
5
 9,776 
 19,552 
2004-12-01
0.6
15
25
 704,443 
 163,573 
2004-09-01
1.9231
25
13
 217,468 
 368,876 
2004-06-01
1.3571
19
14
 129,092 
 11,360 
2004-03-01
0.2308
3
13
 90,555 
 219,094 
2003-12-01
0.6111
11
18
 639,406 
 153,766 
2003-09-01
15.0
30
2
 234,817 
 10,895 
2003-06-01
0.0938
3
32
 43,992 
 389,797 

Medtronic PLC Notable Stakeholders

A Medtronic PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medtronic PLC often face trade-offs trying to please all of them. Medtronic PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medtronic PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Omar IshrakChairman of the Board, Chief Executive OfficerProfile
Bradley LermanSenior Vice President General Counsel, Corporate secretaryProfile
Ryan WeispfenningVice President - Investor RelationsProfile
Hooman HakamiExecutive Vice President and Group President of the Medtronic Diabetes GroupProfile
Richard KuntzSenior Vice President and Chief Scientific, Clinical and Regulatory OfficerProfile
Robert WhiteExecutive Vice President and President of Medtronic’s Minimally Invasive Therapies GroupProfile
Frank ChanPresident MonitoringProfile
Sean SalmonExecutive Vice President and President, Diabetes Operating Unit, President, Cardiovascular PortfolioProfile
Carol SurfaceChief Human Resource Officer, Senior Vice PresidentProfile
Karen ParkhillChief Financial Officer, Executive Vice PresidentProfile
Geoffrey MarthaExecutive Vice President and President - Restorative Therapies GroupProfile
Robert HoedtExecutive Vice President and President - EMEA RegionProfile
Michael CoyleExecutive Vice President, Group President - Cardiac and Vascular GroupProfile
Scott DonnellyLead Independent DirectorProfile
Richard AndersonLead Independent DirectorProfile
Elizabeth NabelIndependent DirectorProfile
James LenehanIndependent DirectorProfile
Craig ArnoldIndependent DirectorProfile
Kendall PowellLead Independent DirectorProfile
Denise OLearyIndependent DirectorProfile
Michael LeavittIndependent DirectorProfile
Randall HoganIndependent DirectorProfile
Andrea GoldsmithIndependent DirectorProfile
Joon HurhVP PacificProfile
Ivan FongGeneral VPProfile
Ivan JDGeneral VPProfile
Brett WallExecutive Vice President and President Restorative Therapies GroupProfile
Jennifer KirkChief Accounting Officer, Global ControllerProfile
Scott CundySenior OfficerProfile
Kenneth WashingtonSenior OfficerProfile
Mark PloofSenior ServicesProfile
Sean LennonChief OfficerProfile
Mei JiangSenior InnovationProfile
John LiddicoatExecutive Vice President and President Americas RegionProfile
Kevin LoftonIndependent DirectorProfile
Olaf HedrichChief OfficerProfile
Sally SabaChief Inclusion and Diversity OfficerProfile
Brad LermanSenior Vice President General Counsel, Corporate secretaryProfile
Matt WalterChief OfficerProfile
Torod NeptuneSenior OfficerProfile
Thierry PietonChief OfficerProfile
Gary CoronaSenior FinanceProfile
Que DallaraExecutive UnitProfile
Gregory SmithExecutive ChainProfile
Robert HopkinsSenior StrategyProfile
MSc MDMedical ScientificProfile
MPH MDChief BusinessProfile

About Medtronic PLC Management Performance

The success or failure of an entity such as Medtronic PLC often depends on how effective the management is. Medtronic PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medtronic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medtronic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.11  0.18 
Return On Capital Employed 0.05  0.05 
Return On Assets 0.04  0.04 
Return On Equity 0.07  0.07 
Please note, the imprecision that can be found in Medtronic PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medtronic PLC. Check Medtronic PLC's Beneish M Score to see the likelihood of Medtronic PLC's management manipulating its earnings.

Medtronic PLC Workforce Analysis

Traditionally, organizations such as Medtronic PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medtronic PLC within its industry.

Medtronic PLC Manpower Efficiency

Return on Medtronic PLC Manpower

Revenue Per Employee340.7K
Revenue Per Executive688.6M
Net Income Per Employee38.7K
Net Income Per Executive78.2M
Working Capital Per Employee117.3K
Working Capital Per Executive237.1M

Additional Tools for Medtronic Stock Analysis

When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.